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Abstract
Background: People with chronic obstructive pulmonary disease (COPD) sometimes experience anxiety, depression
and comorbid cognitive deficits. Rather than being merely a consequence of symptom-related physical impairments
these additional problems may be part of the clinical course of the condition. The relationship between the physical
and psychological aspects of the condition is illustrated by the patterns of use of non-invasive ventilation (NIV); NIV is
often rejected or used inappropriately, resulting in clinical deterioration and an increase in health care costs.
The study aims to analyse the effects of psychological support on the acceptance of, and adherence to, NIV. The primary
outcome will be a latent variable related to indices of use of NIV equipment and adherence to treatment regime; while
survival rates and psychological variables will constitute the secondary outcomes.
Methods: A two-arm randomised controlled trial will be conducted. We aim to recruit 150 COPD patients for whom NIV
is indicated. The experimental group will receive a brief course of psychological support that will include counselling,
relaxation and mindfulness-based exercises. In some cases, it will also include neuropsychological rehabilitation
exercises. Support will be delivered via four to eight meetings at the HD Respiratory Rehabilitation Unit, at home
or via telemedicine. Controls will receive standard care and watch educational videos related to the management
of their disease.
Discussion: This investigation will gain insight about the role of a psychological intervention as part of a treatment
plan during the process of adaptation to NIV in COPD patients.
Trial registration: ClinicalTrials.gov, ID: NCT02499653. Registered on 14 July 2015.
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Background
Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death in the world [1], the
seventh cause of disability-adjusted life years (DALYs)
and the tenth cause of early death (measured as years of
life lost (YLL)) [2]. This clinical condition involves an
irreversible obstruction of the airways, associated with
progressive and chronic inflammation of the lung tissue;
it develops slowly and adversely affects both quality of
life (QoL) and psychological wellbeing [3], leading to
high levels of anxiety and depression [4, 5]. The latter
two are also associated with fatigue, shortness of breath
and an increase in symptom exacerbations [6], engen-
dering a psychological vicious circle of negativity [7–9].
Systematic reviews state that the prevalence of depres-
sion ranges between 7% and 42% [10], whereas that of
anxiety varieties between 10% and 19% [11].
Cognitive deficits, whether global or in specific domains,
such as perception, memory, attention [12–14], learning,
visuospatial and construction abilities and language skills
[15, 16], can also have an impact on functional, social,
emotional and communication skills [17]. Moreover,
COPD is associated with a significant risk of developing
mild cognitive impairment, especially in patients older
than 70 years [18].
Preliminary evidence suggests that it is necessary to
pay attention to psychological factors in both therapy
and rehabilitation [19–21]. Psychological changes may
be a consequence of physical symptoms, but they may
also influence the course of the disease, as in other
chronic conditions [22].
Patterns of acceptance of non-invasive ventilation
(NIV) are examples of the interaction of psychological
and physical factors. Despite the fact that NIV can pro-
duce significant clinical improvement in their condition,
patients often reject it or fail to use it appropriately. NIV
rejection or its inappropriate use results in worse clinical
outcomes and increased health care costs. Appropriate
use of NIV is crucial, given that adherence to medication
decreases over time and is inversely related to the number
of drugs prescribed [23, 24]. Acceptance and adherence to
NIV treatment can reduce hospital admissions and
physician visits [25]. Using NIV requires the patient to
make some behavioural and lifestyle changes, such as
changes in daily routine to allocate time for ventilation,
and this may reduce adherence to the treatment [24].
Treatment adherence may also be adversely affected by the
use of different drugs and devices, or because patients re-
ceive inadequate education about the illness and associated
morbidities from their physician [26, 27].
Clinical experience suggests that patients with cognitive
deficits [12, 28, 29] or psychological problems, such as
anxiety and depression, are less likely to accept and
comply with NIV regimes; however, there has been little
research on this. The few available studies focussed on
early NIV failure (defined as the need for endotracheal in-
tubation or death within 24–48 h of starting NIV) [30, 31],
quantifying adherence [32] and largely neglected predictors
of nonadherence [33]. No study has identified the individ-
ual psychological factors that increase the risk of rejection
or improper use of NIV. Previous studies suggest that
COPD patients who clearly demonstrated a lower survival
benefit from the NIV usage exhibit worse average daily
NIV adherence, because of the imbalance between the
constraints that NIV imposes and the improvement that
patients’ perceive in their condition [34]. Ventilator settings
are not easy to adjust and they influence sleep quality,
which has spill-over effects on daytime life [34, 35]. The ef-
fects of psychological support in promoting the machine’s
acceptance have also not been adequately investigated.
Objectives
The primary objective of the study is to evaluate the
effects of psychological support on the acceptance of,
and adherence to, NIV. Secondary aims include assess-
ment of the change in QoL between baseline and after 3,
6 and 12 months following recruitment, identification of
psychological and clinical factors that predict rejection
or misuse of NIV, and factors that predict the success of
the psychological intervention.
The primary outcome will be a latent variable related
to indices of use of NIV equipment and adherence to
treatment regime: the effects on change from baseline in
acceptance to NIV in COPD patients at 3, 6 and 12
months as measured by weekly means and standard
deviations of hours of use of NIV as recorded by the
ventilator and changes in adherence defined as the
difference between prescribed and effective NIV hours.
Change in QoL will also be measured relative to baseline
at 3, 6 and 12 months using the EuroQoL (EQ-5D)
questionnaire, respiratory, functional and biomedical
parameters. Survival rates after starting the adaptation
to NIV and psychological variables will be considered as
secondary outcomes.
As well as evaluating clinical and psychological variables
we will also evaluate econometric outcomes. The study
will explore the potential impact of the psychological
intervention on the cost to the Italian welfare system of
providing health care for patients with COPD. These as-
sessments will be based on standard econometric indices
(e.g. quality-adjusted life years (QALYs); DALYs).
Finally, semistructured interviews will be conducted to
gain insight into patients’ perceptions of NIV.
Methods
Informed consent and ethical considerations
The study was approved by the Ethics Committee of the
IRCCS Fondazione Don Carlo Gnocchi. The Study was
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registered at ClinicalTrials.gov, ID: NCT02499653.
Amendments will be submitted to both the Ethics
Committee and the Clinical Trials Register. All subjects will
provide written, informed consent before the study begins.
In particular, a psychologist will discuss the trial with pa-
tients in light of the information provided in the Consent
Form and in Information Sheets. Patients will then be able
to have an informed discussion with the participating con-
sultant. The psychologist will obtain written consent from
patients who are willing to participate in the trial.
All study-related information will be stored securely at the
study site. All participant information will be stored in
locked file cabinets in areas with limited access at Fonda-
zione Don Carlo Gnocchi, Milan. All laboratory specimens,
reports, data collection, process and administrative forms
will be identified by a coded ID (identification) number only
to maintain participant confidentiality. All records that con-
tain names or other personal identifiers, such as Locator
Forms and Informed Consent Forms, will be stored separ-
ately from study records identified by code number. All local
databases will be secured with password-protected access
systems. Participants’ study information will not be released
outside of the study without the written permission of the
participants. Moreover, the principal investigators will be the
only persons allowed direct access to the data sets, and will
also have access to other sites’ data by request. To ensure
confidentiality, data dispersed to project team members will
be blinded of any identifying participant information.
Subjects and setting
The study will be conducted in a Clinical and Research
Centre, HD Respiratory Rehabilitation Unit, Fondazione
Don Carlo Gnocchi, IRCCS Santa Maria Nascente,
Milan (Italy), a centre chosen based on documentation
of, among other things, patient availability.
We aim to recruit 150 patients with COPD who have
been recommended to use NIV based on the GOLD
criteria (from moderate to severe) [36, 37].
The inclusion criteria are as follows: age 18 years or
older; inpatients or outpatients; with moderate (GOLD
2–50% ≤ FEV1 < 80% predicted) to severe (GOLD 3–
30% ≤ FEV1 < 50% predicted) COPD.
The exclusion criteria are as follows: refusal of consent;
pregnancy; oncological history or history of psychiatric/
mental disorders, according to Diagnostic and Statistical
Manual of Mental Disorders, fifth edition (DSM-V) cri-
teria [38, 39], with the exception of anxiety and depres-
sion, as indicated in the patient’s clinical record;
immunosuppressive disease as the principal condition;
stable use of antidepressant drugs.
Design and interventions
This study is a randomised control trial (RCT) (for the
flowchart of the study design, see Fig. 1).
Subjects in the experimental group will receive a brief
psychological intervention in addition to standard. This
will include counselling and psychological support,
mindfulness-based cognitive restructuring exercises [40]
and relaxation training [41]. The intervention will also
include neuropsychological rehabilitation exercises if
required; this will be decided on a case-by-case basis,
using clinical notes and the Addenbrooke’s Cognitive
Examination (ACE-R) and Confusion Assessment Method
(CAM) scores. Each patient’s psychological needs will be
assessed at the beginning of the psychological intervention,
paying special attention to aspects related to the disease
(e.g. perception, understanding, awareness of symptoms).
Thereafter, the psychological intervention will give more
importance to the risks, doubts and fears arising from use
of NIV. The intervention will consist of cognitive refram-
ing exercises, relaxation training and, if necessary, neuro-
psychological rehabilitation exercises. Specifically, these
intervention components extend from lowering arousal to
providing disease information and management in order to
understand better how to cope with NIV and with COPD
symptoms, to an emotionally supportive environment in
which subjects can address their fears and anxieties, as well
as behavioural and cognitive coping strategies. The dur-
ation of the intervention will vary from a minimum of four
weekly sessions to a maximum of eight according to the
needs of the patient. Each session will last about 30–45
min. Sessions will be conducted in a hospital setting, or at
the patients’ house or via telemedicine if patients are
unable to attend the hospital.
Subjects assigned to the control group will spend six
sessions watching videos related to the management of
their disease (sessions will last about 30 min).
The psychologists who conduct the intervention will
be blind to the assessments and vice versa (for the
study procedure: schedule of enrolment, interventions
and assessments, which reflects the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
figure, see Fig. 2).
Sample size
Based on statistical analysis, preventive inherent power and
sample size [40] we anticipate that the study will require 150
subjects. We will recruit between 128 subjects (statistical
power of 0.80; α = 0.05; 1− β= 0.80; t (126) =1.97) and 172
subjects (statistical power equal to 0.90; α = 0.05; 1 − β=
0.90; t (170) = 1.97). The inherent power also emphasises
that such analyses have been carried out using data for a sci-
entific study that have a comparable primary outcome [33].
Randomisation
Sequence generation
The patients will be randomised through a simple
method, extracting a unit from the population using a
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method which guarantees the causality of the extractions
(https://www.random.org).
Allocation concealment and implementation
Randomisation will be implemented using a computer
system and the sequence will be concealed using a
centralised service, since this cannot be subverted by
either investigators or assessors and provides inde-
pendent verification preventing the investigators to
know the allocation sequence in advance until subjects
are assigned to groups. We will calculate the dropout
rate for both groups.
Blinding (masking)
Subjects will not know in advance to which group they will
be assigned and that the kind of treatment between control
and experimental groups is different. Assessors will be
blind to group allocation. A debriefing will be provided at
the end of the study: the psychologist who carried out the
intervention will debrief with the patients and will send
them a report about the study’s findings.
Assessment
Sociodemographic variables
At the first assessment we will collect sociodemographic
information (age, gender, weight, height, level of education,
current job and/or previous employment, cohabitation,
smoking and alcohol consumption, current and historical
levels of physical activity, duration of disease, drug therapies
for respiratory disease, use of psychotropic drugs, number
of hospital admissions during the last year, exacerbations
and comorbidities).
Medical and clinical assessment
This will cover:
 NIV use (prescribed hours, effective hours and their
difference)
 The effects on change from baseline in acceptance of
NIV in COPD patients as measured by weekly means
and standard deviations of hours of use of NIV as
recorded by the ventilator
 Changes in adherence defined as the difference
between prescribed and effective NIV hours
 Survival rate at different time after starting the
adaptation to NIV, reported in terms of months
 Simple spirometry: forced expiratory volume in the first
second (FEV1); forced vital capacity (FVC); FEV1/FVC
 Fatigue, measured by the Fatigue Severity Scale
(FSS) [42]
 Emogasanalysis (EGA): potential of hydrogen
(pH); partial pressure of oxygen in arterial blood
Fig. 1 Flowchart of the study design
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Fig. 2 Study procedure: schedule of enrolment, interventions and assessments, reflecting the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) figure
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(PaO2); partial pressure of carbon dioxide in
arterial blood (PaCO2); hydrogen carbonate
concentration (HCO3)
Psychological assessment
Anxiety and depression Anxiety and depression will be
assessed using the 14-item Hospital Anxiety and Depres-
sion Scale (HADS) [43]. Responses refer to the previous
week and are given using a four-point Likert scale. The
scale is designed to assess the severity of anxiety and
depression simultaneously; it is organised into two 7-item
subscales, HADS-A and HADS-D, which generate separ-
ate subscores for anxiety and depression, respectively.
Quality of life QoL will be assessed using the EuroQoL
(EQ-5D) [44, 45], a short, simple questionnaire consisting
of two sections. The first comprises five health-related
items (covering mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression), and is used to assess the se-
verity of health problems. The second section comprises a
Visual Analogue Scale – a representation of a thermometer
with graduated markings which respondents use to indicate
their perception of their current health status (0 = ‘worst
possible health state’ to 100 = ‘best possible health state’).
Representation of the disease The representation that
the patient has of their disease will be assessed using the
Brief Illness Perception Questionnaire (BIPQ), developed
by Broadbent and colleagues [46, 47]. This can be viewed
as a practical application of the theory of self-regulation.
Items can be organised into three categories: (1) identity
of the disease (14 items), (2) opinion of the disease (38
items) and (3) causes of the disease (18 items). Responses
are given using a five-point Likert scale (1 = ‘strongly
disagree’ to 5 = ‘strongly agree’).
Representation of proposed therapies This assessment
will be based on a modified version of the Beliefs about
Medicines Questionnaire (BMQ) developed by Horne
and colleagues [48]. This tool is used to assess patients’
beliefs about medication. It consists of two scales: Specific
Beliefs and General Beliefs. We will use a modified version
of the BMQ designed to capture beliefs about NIV.
Therapeutic compliance This will be assessed using the
Questionario sull’Adesione alla Terapia Farmacologica e
Dietetica (QAF) [49]. The QAF consists of 19 items to
which responses are given using a four-point Likert scale
(1 = ‘this is always true of me’; 2 = ‘this is often true of
me’; 3 = ‘this is almost never true of me’; 4 = ‘this is never
true of me’). Some of the items in this questionnaire are
modifications of items of the Medication Adherence
Rating Scale (MARS) which is used in psychiatry to assess
adherence to drug therapy. The items were compiled and
assorted randomly through extraction.
Self-esteem Self-esteem will be assessed with the 10-
item Rosenberg Self-Esteem Scale (RSES) [50]; responses
are given on a four-point Likert scale (1 = ‘strongly agree’
to 4 = ‘strongly disagree’). The scale provides an indica-
tion of overall self-esteem and sense of self-worth.
Cognitive assessment
Addenbrooke’s Cognitive Examination (ACE-R) The
ACE-R [51] is a brief cognitive test that assesses five
aspects of cognition: attention/orientation (AO), mem-
ory (M), verbal fluency (F), language (L) and visuospatial
abilities (VS). Administration of the ACE-R takes 15 min
on average.
Confusion Assessment Method (CAM) This tool will
enable us to evaluate features considered to be of great
diagnostic importance, namely: acute onset, attentional
deficits, disorganisation of thought, altered level of con-
sciousness, disorientation, memory deficits, disorders of
perception, psychomotor agitation, psychomotor retard-
ation and disturbance of the sleep-wake cycle [52].
Econometric assessment
We will analyse the direct (e.g. supply of equipment, main-
tenance tasks, etc.) and indirect (e.g. cost of hospitalisation
for relapse, additional care, indirect social costs, etc.) costs
of the management of COPD in our sample, referring to
clinical notes and medical files. Changes in QoL and life
expectancy data will be used to estimate QALYs [53, 54]
and DALYs [55] and, by comparing our data with inter-
national norms, we will gain insight into the sustainability
and cost-efficiency of the psychological intervention. We
also plan to use econometric tools such as the Work
Productivity and Activity Impairment Questionnaire –
Respiratory Symptoms (WPAI-RS) [56, 57].
The medical assessment will take about 30 min and
the psychological assessment about 45–50 min. The
order of administration of the questionnaires and tests
will be randomised on a per subject basis.
Finally, semistructured interviews (qualitative data)
will be carried out to provide insight into subjects’ views
on use of the NIV equipment.
Recruitment and duration of the study
The study is expected to last 3 years. After the pulmonary
clinical visit all patients who meet the inclusion criteria
will be asked to join the study. If they agree to do so they
will be asked to sign a form to indicate their informed
consent to participate. After this they will undergo
psychological assessment (baseline, T0). Follow-up as-
sessments will be carried out 3, 6 and 12 months after
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recruitment (T1, T2 and T3, respectively) using the
same procedure.
Proposed analyses
Descriptive analyses will be performed for all study
variables. We will assess the effect of the interaction
between treatment (experimental versus control) and
time (three repeated measures) on primary outcome
variables (acceptance of treatment; adherence to treat-
ment). Missing data will be imputed with multiple im-
putation techniques [58, 59].
Before-after differences will be analysed with appropriate
within-group tests (paired samples t test; Wilcoxon test).
Multiple regression will be used to assess the influence of
baseline variables on outcome indicators and identify pre-
dictor variables.
The analysis will be performed using the intention-to-
treat procedure. The significance level will be 5% (p ≤ 0.05).
Data analysis will be performed using SPSS software.
Data collection and analysis will begin in month 1 and
will last for 24 months, i.e. until 1 month after the last
follow-up data have been collected.
We will report reasons for withdrawal for each random-
isation group and compare the reasons qualitatively. The
effect that any missing data might have on results will be
assessed via sensitivity analysis of augmented data sets.
Dropouts (essentially, participants who withdraw consent
for continued follow-up) will be included in the analysis
by modern imputation methods for missing data.
For more details about the trial, refer to the SPIRIT
Checklist (Additional file 1).
Discussion
We anticipate some limitations or threats to the efficacy
of the study protocol. First, the rigorous RCT design will
be in contrast with the ‘single-patient’ approach. As part
of the ‘single-patient’ approach patients will be free to
choose the setting in which they receive the intervention;
this may make it difficult to achieve an even distribution
of settings. Third, patients who choose to use telemedicine
might face difficulty accessing the intervention owing to
technical problems.
Despite these limitations the design has many strengths.
It investigates a form of psychological support specifically
designed to facilitate adaptation to NIV. Moreover, the
intervention will be tailored to patients’ needs and clinical
status. The study protocol is projected in order to reduce
barriers to participation such as disabilities (i.e. move-
ments, dyspnoea) and practical barriers (daily activities
and habits). Finally, to reduce the Hawthorne effect the
experimental condition will be compared with an active
control group, which will watch films related to the man-
agement of many aspects of COPD.
This study has the potential to demonstrate the viability
of an easy-access intervention based on a ‘single-patient’
approach that can be used in several settings to facilitate
adaptation to NIV and improve the QoL of COPD patients.
This study protocol describes the development of the study
design and the related intervention. If the hypothesis is
confirmed, the intervention will have positive effects on
physical and psychological wellbeing, and consequently
reduce the costs of health care for COPD patients.
Trial status
Recruitment is ongoing.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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